Abstract

Protocol Specific Research Support (PSRS) supports the conduct of innovative, high-priority phase I and phase l-ll investigator-initiated trials led by AECC investigators. In order to be eligible for PSRS, the study must be led by AECC investigator or resulted from previous clinical or preclinical studies performed at AECC (with AECOM faculty as co-investigator). A process has been established for designating PSRS, which includes a screen by the CPDMU for eligibility, evaluating the scientific merit of the study (as determined by the PRMC), and assigning priority relative to other AECC investigator-initiated trials. During the last funding period, trials supported by PSRS included protocols evaluating the clinical and immune effects of an HspE7 vaccine in patients with CINIII, the clinical and biologic effects of combining the farnesyltransferase inhibitor tipifarnib with standard chemotherapy in locally advanced breast cancer, and defining the recommended phase II dose, pharmacokinetics, and pharmacodynamics of the epothilone B analog ixabepilone. These studies have led to additional CTEP-sponsored and industry-sponsored phase II and phase III trials evaluating the effects of HsPE7 patients with CINIII, tipifarnib in locally advanced breast cancer, and ixabepilone in patients with advanced breast cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-38
Application #
8113385
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
38
Fiscal Year
2010
Total Cost
$240,820
Indirect Cost

  Institution

Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461

  Publications

Agalliu, Ilir; Chen, Zigui; Wang, Tao et al. (2018) Oral Alpha, Beta, and Gamma HPV Types and Risk of Incident Esophageal Cancer. Cancer Epidemiol Biomarkers Prev 27:1168-1175
Bhargava, Ragini; Sandhu, Manbir; Muk, Sanychen et al. (2018) C-NHEJ without indels is robust and requires synergistic function of distinct XLF domains. Nat Commun 9:2484
Collu, Giovanna M; Jenny, Andreas; Gaengel, Konstantin et al. (2018) Prickle is phosphorylated by Nemo and targeted for degradation to maintain Prickle/Spiny-legs isoform balance during planar cell polarity establishment. PLoS Genet 14:e1007391
Doyle, Christopher R; Moon, Jee-Young; Daily, Johanna P et al. (2018) A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice. Infect Immun 86:
Anayannis, Nicole V; Schlecht, Nicolas F; Ben-Dayan, Miriam et al. (2018) Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. PLoS One 13:e0191581
Stepankova, Martina; Bartonkova, Iveta; Jiskrova, Eva et al. (2018) Methylindoles and Methoxyindoles are Agonists and Antagonists of Human Aryl Hydrocarbon Receptor. Mol Pharmacol 93:631-644
Maggi, Elaine C; Gravina, Silvia; Cheng, Haiying et al. (2018) Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model. Front Genet 9:6
Ingram, Jessica R; Blomberg, Olga S; Rashidian, Mohammad et al. (2018) Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A 115:3912-3917
Dulyaninova, Natalya G; Ruiz, Penelope D; Gamble, Matthew J et al. (2018) S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms. Mol Biol Cell 29:632-642
Chen, Zigui; Schiffman, Mark; Herrero, Rolando et al. (2018) Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology 516:86-101

Showing the most recent 10 out of 1508 publications